Observing ketamine and Spravato for depression
Treatments studied
Part of Mental health clinical trials.
This study follows people who are already taking or about to start IV ketamine or Spravato® for hard-to-treat depression. Researchers want to learn more about how these treatments work in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recently started (within 75 days) or are about to start IV ketamine or Spravato® for depression.
- You are 18 years or older.
- Your depression is moderate to severe and has not improved after trying at least two other antidepressants.
- You do not have psychotic features, bipolar disorder, or a psychotic disorder like schizophrenia.
- You do not have an active or recent (within the past year) substance use disorder, except for nicotine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares the effectiveness of esketamine (Spravato) and another similar drug, ketamine, for adults with major depression that has not improved after trying at least two other antidepressants. It aims to find out which treatment works better.
This study tests how a single dose of ketamine affects certain brain and body markers in people with severe depression. It aims to find better ways to predict who will respond to ketamine, which may help personalize depression treatment in the future.
This trial tests whether a single dose of ketamine can quickly improve depression by studying brain chemical changes using MRI. It's for people with treatment-resistant depression who haven't used ketamine before.
This early-stage study looks at how parts of brain cells respond to ketamine in people with depression who have not improved with usual antidepressants. It may help researchers find why ketamine works for some people and not others, and who might benefit.
This trial studies how ketamine affects brain circuits in people with depression compared to healthy volunteers. It involves a single infusion of ketamine and brain scans before and after.
This study tests whether ketamine can help reduce suicidal thoughts in people with depression. It also looks at how ketamine affects a brain receptor that may be linked to mood and stress, to learn why it might help.
Hear when a new Major Depression Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.